The Drugs to Watch at ESMO in 2024

As part of our Drugs to Watch™ program, Clarivate oncology experts pored over abstracts submitted to the 2024 ESMO Congress to identify 11 particularly striking results, along with an additional three of import to the fast-growing Mainland China market. Read our new report in which they lay out the context, key findings and potential market impact of each.

This year’s ESMO Drugs to Watch include:

• Adjuvant Tecentriq plus bevacizumab in resected or ablated high-risk hepatocellular carcinoma
• Neoadjuvant Keytruda plus chemotherapy followed by adjuvant Keytruda in high-risk stage II-III triple-negative breast cancer
• Perioperative Imfinzi plus chemotherapy in cisplatin-eligible muscle-invasive bladder cancer (MIBC)
• Disitamab vedotin in combination with Keytruda in HER2-expressing locally advanced or metastatic urothelial carcinoma
• Zynyz with carboplatin-paclitaxel in chemotherapy-naive anal cancer
• Mixed phase 2 data for Opdualag in first-line advanced NSCLC
• Truqap plus paclitaxel as first-line treatment of metastatic triple negative breast cancer
• The addition of Lenvima and Keytruda to TACE in intermediate-stage hepatocellular carcinoma
• PSMA-targeted radioligand 177Lu-PNT2002 in mCRPC
• The combination of Cabometyx and Tecentriq in metastatic castration-resistant prostate cancer
• RP1 plus Opdivo in anti-PD-1-failed unresectable or metastatic malignant melanoma

And for Mainland China:

• AnDeWei in combination with anlotinib in previously untreated advanced renal cell carcinoma (RCC)
• QL-1706 in first-line advanced hepatocellular carcinoma (HCC) patients
• SHR-1701 plus chemotherapy as first-line therapy in patients with unresectable locally advanced or metastatic HER2-negative gastric or GEJ adenocarcinoma